Compare Manhattan Associates Inc (MANH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Neurocrine Biosciences Inc — how do they compare? Manhattan Associates Inc trades at $159.61 (market cap $9.79B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| MANH | NBIX | |
|---|---|---|
Market Cap | $9.79B | $17.40B |
Sector | Technology | Health |
52-Week High | $227.94 | $180.55 |
52-Week Low | $120.88 | $123.10 |
Enterprise Value | $9.62B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $165.51, up 1.42% today, with strong technical momentum and bullish moving averages. The company shows robust profitability with a 19.68% net income margin and has beaten EPS estimates for three consecutive quarters. However, valuation ratios like a P/E of 46.37 suggest premium pricing. Recent news highlights an ongoing legal investigation into fiduciary duties by directors, while analyst consensus remains strongly positive with a $192.80 price target.
The outlook for MANH is cautiously optimistic, driven by consistent earnings beats and solid cash flow generation. Key opportunities include sustained cloud and AI adoption, but risks involve high valuation multiples, competitive pressures, and potential legal overhangs from the Rosen Law Firm investigation. Investors should weigh strong fundamentals against elevated price levels and external uncertainties.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
